Walpar Nutritions（WALPAR）株式概要ウォルパー・ニュートリションズ社は、医薬品、栄養補助食品、ハーブ、アーユルヴェーダ商品の製造と取引を行っている。 詳細WALPAR ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金0/6報酬株価収益率（ 14 x） Indian市場（ 23.5 x）を下回っています。リスク分析Indian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( ₹327M )最新の財務報告は6か月以上前のものである すべてのリスクチェックを見るWALPAR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW474,562 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA474,562 investors already sharing narrativesYour Fair Value₹Current Price₹34.8586.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0757m2016201920222025202620282031Revenue ₹757.5mEarnings ₹23.3mAdvancedSet Fair ValueView all narrativesWalpar Nutritions Limited 競合他社Deccan Health CareSymbol: BSE:542248Market cap: ₹293.5mSandu PharmaceuticalsSymbol: BSE:524703Market cap: ₹381.6mNovateor Research LaboratoriesSymbol: BSE:542771Market cap: ₹198.8mRavelcareSymbol: BSE:544629Market cap: ₹788.4m価格と性能株価の高値、安値、推移の概要Walpar Nutritions過去の株価現在の株価₹34.8552週高値₹50.6052週安値₹21.25ベータ-0.571ヶ月の変化25.36%3ヶ月変化-5.81%1年変化-25.77%3年間の変化-15.62%5年間の変化54.89%IPOからの変化22.28%最新ニュースValuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹28.50, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 38x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹309.4m market cap, or US$3.26m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).Board Change • Apr 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 13Walpar Nutritions Limited to Report First Half, 2026 Results on Nov 13, 2025Walpar Nutritions Limited announced that they will report first half, 2026 results on Nov 13, 2025最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹28.50, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 38x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹309.4m market cap, or US$3.26m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).Board Change • Apr 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jan 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 13Walpar Nutritions Limited to Report First Half, 2026 Results on Nov 13, 2025Walpar Nutritions Limited announced that they will report first half, 2026 results on Nov 13, 2025Board Change • Nov 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Sep 04Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025, at 12:00 Indian Standard Time.分析記事 • Jul 19Fewer Investors Than Expected Jumping On Walpar Nutritions Limited (NSE:WALPAR)Walpar Nutritions Limited's ( NSE:WALPAR ) price-to-earnings (or "P/E") ratio of 20.1x might make it look like a buy...New Risk • May 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹438.7m market cap, or US$5.13m). Minor Risks High level of debt (46% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change).分析記事 • Sep 28Walpar Nutritions Limited (NSE:WALPAR) Stock's 26% Dive Might Signal An Opportunity But It Requires Some ScrutinyWalpar Nutritions Limited ( NSE:WALPAR ) shares have had a horrible month, losing 26% after a relatively good period...Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹52.30, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 66x in the Personal Products industry in India. Total returns to shareholders of 185% over the past three years.分析記事 • Sep 07Does Walpar Nutritions (NSE:WALPAR) Deserve A Spot On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...分析記事 • Jul 27Market Might Still Lack Some Conviction On Walpar Nutritions Limited (NSE:WALPAR) Even After 26% Share Price BoostThose holding Walpar Nutritions Limited ( NSE:WALPAR ) shares would be relieved that the share price has rebounded 26...お知らせ • Jul 09Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024, at 12:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹115, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 59x in the Personal Products industry in India. Total returns to shareholders of 51% over the past year.Valuation Update With 7 Day Price Move • May 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹129, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 57% over the past year.New Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹543.6m market cap, or US$6.54m). Minor Risks High level of debt (56% net debt to equity). Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).New Risk • May 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$10m (₹558.1m market cap, or US$6.68m). Minor Risk High level of debt (56% net debt to equity).Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹122, the stock trades at a trailing P/E ratio of 40.5x. Average trailing P/E is 53x in the Personal Products industry in India. Total returns to shareholders of 137% over the past year.Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹116, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 85% over the past year.分析記事 • Feb 14With EPS Growth And More, Walpar Nutritions (NSE:WALPAR) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹94.70, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 61x in the Personal Products industry in India. Total returns to shareholders of 50% over the past year.Reported Earnings • Nov 11First half 2024 earnings releasedFirst half 2024 results: EPS: ₹0.85. Net income: ₹3.97m (up ₹3.97m from 1H 2023).Reported Earnings • Oct 12Full year 2023 earnings released: EPS: ₹1.30 (vs ₹0.90 in FY 2022)Full year 2023 results: EPS: ₹1.30 (up from ₹0.90 in FY 2022). Revenue: ₹353.6m (up 32% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue.お知らせ • Sep 27Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023, at 11:19 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on 31 March 2023 and Statement of Profit and Loss together with the notes forming part thereof along with Cash Flow Statement for the financial year ended on that date, and the Reports of the Board of Directors (The Board) and the Auditors thereon; and to consider Board changes.分析記事 • Sep 18Here's Why Walpar Nutritions (NSE:WALPAR) Has Caught The Eye Of InvestorsFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹86.35, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 50x in the Personal Products industry in India. Total returns to shareholders of 118% over the past year.分析記事 • May 25We Ran A Stock Scan For Earnings Growth And Walpar Nutritions (NSE:WALPAR) Passed With EaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • May 24Full year 2023 earnings released: EPS: ₹2.51 (vs ₹0.90 in FY 2022)Full year 2023 results: EPS: ₹2.51 (up from ₹0.90 in FY 2022). Revenue: ₹354.8m (up 33% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹59.40, the stock trades at a trailing P/E ratio of 70.9x. Average trailing P/E is 51x in the Personal Products industry in India. Total returns to shareholders of 123% over the past year.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹61.25, the stock trades at a trailing P/E ratio of 73.1x. Average trailing P/E is 57x in the Personal Products industry in India. Total returns to shareholders of 101% over the past year.分析記事 • Sep 29If EPS Growth Is Important To You, Walpar Nutritions (NSE:WALPAR) Presents An OpportunityThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹59.55, the stock trades at a trailing P/E ratio of 71x. Average trailing P/E is 63x in the Personal Products industry in India. Total returns to shareholders of 65% over the past year.分析記事 • Jul 22Walpar Nutritions Limited's (NSE:WALPAR) P/E Is Still On The Mark Following 26% Share Price BounceDespite an already strong run, Walpar Nutritions Limited ( NSE:WALPAR ) shares have been powering on, with a gain of...Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 46.6x. Average trailing P/E is 47x in the Personal Products industry in India. Total loss to shareholders of 12% over the past year.Recent Insider Transactions • Jul 18Executive Director & CFO recently bought ₹2.4m worth of stockOn the 14th of July, Sejal Ladhawala bought around 68k shares on-market at roughly ₹34.77 per share. This was the largest purchase by an insider in the last 3 months. This was Sejal's only on-market trade for the last 12 months.お知らせ • Feb 03Walpar Nutritions Limited Announces Resignation of Mr. Parin Patel from the Post of Independent DirectorWalpar Nutritions Limited announced that company had submitted intimation of resignation of Mr. Parin Patel from the post of Independent Director of the Company on 11th January, 2022. Resignation is w.e.f. 11th January, 2022 due to his appointment as Business Development Manager in the Company.Executive Departure • Aug 28Company Secretary & Compliance Officer Palakben Joshi has left the companyOn the 25th of August, Palakben Joshi's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Palakben's name. Palakben is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.株主還元WALPARIN Personal ProductsIN 市場7D0%-0.4%0.6%1Y-25.8%-10.6%1.3%株主還元を見る業界別リターン: WALPAR過去 1 年間で-10.6 % の収益を上げたIndian Personal Products業界を下回りました。リターン対市場: WALPARは、過去 1 年間で1.3 % のリターンを上げたIndian市場を下回りました。価格変動Is WALPAR's price volatile compared to industry and market?WALPAR volatilityWALPAR Average Weekly Movement9.2%Personal Products Industry Average Movement5.0%Market Average Movement6.0%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%安定した株価: WALPARの株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のWALPARのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2009n/aKalpesh Ladhawalawww.walparnutritions.comウォルパー・ニュートリションズ社は、医薬品、栄養補助食品、ハーブ、アーユルヴェーダ商品の製造と取引を行っている。また、栄養補助食品やハーブ製品の受託製造、栄養補助食品の製造に使用される原材料の取引も行っている。同社は2009年に設立され、インドのガンディナガルに拠点を置く。もっと見るWalpar Nutritions Limited 基礎のまとめWalpar Nutritions の収益と売上を時価総額と比較するとどうか。WALPAR 基礎統計学時価総額₹327.26m収益（TTM）₹23.31m売上高(TTM)₹757.46m14.0xPER（株価収益率0.4xP/SレシオWALPAR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計WALPAR 損益計算書（TTM）収益₹757.46m売上原価₹589.45m売上総利益₹168.00mその他の費用₹144.69m収益₹23.31m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）2.48グロス・マージン22.18%純利益率3.08%有利子負債／自己資本比率41.1%WALPAR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 20:10終値2026/07/20 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Walpar Nutritions Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹28.50, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 38x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹309.4m market cap, or US$3.26m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).
Board Change • Apr 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 13Walpar Nutritions Limited to Report First Half, 2026 Results on Nov 13, 2025Walpar Nutritions Limited announced that they will report first half, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹27.80, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 39x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.
Valuation Update With 7 Day Price Move • Jun 04Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹28.50, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 38x in the Personal Products industry in India. Total loss to shareholders of 27% over the past three years.
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Market cap is less than US$10m (₹309.4m market cap, or US$3.26m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end).
Board Change • Apr 06Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jan 29Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 13Walpar Nutritions Limited to Report First Half, 2026 Results on Nov 13, 2025Walpar Nutritions Limited announced that they will report first half, 2026 results on Nov 13, 2025
Board Change • Nov 10Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Non Executive Independent Director Tapan Patel was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Sep 04Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025Walpar Nutritions Limited, Annual General Meeting, Sep 25, 2025, at 12:00 Indian Standard Time.
分析記事 • Jul 19Fewer Investors Than Expected Jumping On Walpar Nutritions Limited (NSE:WALPAR)Walpar Nutritions Limited's ( NSE:WALPAR ) price-to-earnings (or "P/E") ratio of 20.1x might make it look like a buy...
New Risk • May 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹438.7m market cap, or US$5.13m). Minor Risks High level of debt (46% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change).
分析記事 • Sep 28Walpar Nutritions Limited (NSE:WALPAR) Stock's 26% Dive Might Signal An Opportunity But It Requires Some ScrutinyWalpar Nutritions Limited ( NSE:WALPAR ) shares have had a horrible month, losing 26% after a relatively good period...
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹52.30, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 66x in the Personal Products industry in India. Total returns to shareholders of 185% over the past three years.
分析記事 • Sep 07Does Walpar Nutritions (NSE:WALPAR) Deserve A Spot On Your Watchlist?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
分析記事 • Jul 27Market Might Still Lack Some Conviction On Walpar Nutritions Limited (NSE:WALPAR) Even After 26% Share Price BoostThose holding Walpar Nutritions Limited ( NSE:WALPAR ) shares would be relieved that the share price has rebounded 26...
お知らせ • Jul 09Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024Walpar Nutritions Limited, Annual General Meeting, Jul 30, 2024, at 12:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹115, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 59x in the Personal Products industry in India. Total returns to shareholders of 51% over the past year.
Valuation Update With 7 Day Price Move • May 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹129, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 57% over the past year.
New Risk • May 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹543.6m market cap, or US$6.54m). Minor Risks High level of debt (56% net debt to equity). Latest financial reports are more than 6 months old (reported September 2023 fiscal period end).
New Risk • May 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Market cap is less than US$10m (₹558.1m market cap, or US$6.68m). Minor Risk High level of debt (56% net debt to equity).
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹122, the stock trades at a trailing P/E ratio of 40.5x. Average trailing P/E is 53x in the Personal Products industry in India. Total returns to shareholders of 137% over the past year.
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹116, the stock trades at a trailing P/E ratio of 38.5x. Average trailing P/E is 55x in the Personal Products industry in India. Total returns to shareholders of 85% over the past year.
分析記事 • Feb 14With EPS Growth And More, Walpar Nutritions (NSE:WALPAR) Makes An Interesting CaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹94.70, the stock trades at a trailing P/E ratio of 31.5x. Average trailing P/E is 61x in the Personal Products industry in India. Total returns to shareholders of 50% over the past year.
Reported Earnings • Nov 11First half 2024 earnings releasedFirst half 2024 results: EPS: ₹0.85. Net income: ₹3.97m (up ₹3.97m from 1H 2023).
Reported Earnings • Oct 12Full year 2023 earnings released: EPS: ₹1.30 (vs ₹0.90 in FY 2022)Full year 2023 results: EPS: ₹1.30 (up from ₹0.90 in FY 2022). Revenue: ₹353.6m (up 32% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue.
お知らせ • Sep 27Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023Walpar Nutritions Limited, Annual General Meeting, Sep 26, 2023, at 11:19 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on 31 March 2023 and Statement of Profit and Loss together with the notes forming part thereof along with Cash Flow Statement for the financial year ended on that date, and the Reports of the Board of Directors (The Board) and the Auditors thereon; and to consider Board changes.
分析記事 • Sep 18Here's Why Walpar Nutritions (NSE:WALPAR) Has Caught The Eye Of InvestorsFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹86.35, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 50x in the Personal Products industry in India. Total returns to shareholders of 118% over the past year.
分析記事 • May 25We Ran A Stock Scan For Earnings Growth And Walpar Nutritions (NSE:WALPAR) Passed With EaseThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • May 24Full year 2023 earnings released: EPS: ₹2.51 (vs ₹0.90 in FY 2022)Full year 2023 results: EPS: ₹2.51 (up from ₹0.90 in FY 2022). Revenue: ₹354.8m (up 33% from FY 2022). Net income: ₹5.90m (up 55% from FY 2022). Profit margin: 1.7% (up from 1.4% in FY 2022). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹59.40, the stock trades at a trailing P/E ratio of 70.9x. Average trailing P/E is 51x in the Personal Products industry in India. Total returns to shareholders of 123% over the past year.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹61.25, the stock trades at a trailing P/E ratio of 73.1x. Average trailing P/E is 57x in the Personal Products industry in India. Total returns to shareholders of 101% over the past year.
分析記事 • Sep 29If EPS Growth Is Important To You, Walpar Nutritions (NSE:WALPAR) Presents An OpportunityThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Valuation Update With 7 Day Price Move • Aug 23Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹59.55, the stock trades at a trailing P/E ratio of 71x. Average trailing P/E is 63x in the Personal Products industry in India. Total returns to shareholders of 65% over the past year.
分析記事 • Jul 22Walpar Nutritions Limited's (NSE:WALPAR) P/E Is Still On The Mark Following 26% Share Price BounceDespite an already strong run, Walpar Nutritions Limited ( NSE:WALPAR ) shares have been powering on, with a gain of...
Valuation Update With 7 Day Price Move • Jul 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 46.6x. Average trailing P/E is 47x in the Personal Products industry in India. Total loss to shareholders of 12% over the past year.
Recent Insider Transactions • Jul 18Executive Director & CFO recently bought ₹2.4m worth of stockOn the 14th of July, Sejal Ladhawala bought around 68k shares on-market at roughly ₹34.77 per share. This was the largest purchase by an insider in the last 3 months. This was Sejal's only on-market trade for the last 12 months.
お知らせ • Feb 03Walpar Nutritions Limited Announces Resignation of Mr. Parin Patel from the Post of Independent DirectorWalpar Nutritions Limited announced that company had submitted intimation of resignation of Mr. Parin Patel from the post of Independent Director of the Company on 11th January, 2022. Resignation is w.e.f. 11th January, 2022 due to his appointment as Business Development Manager in the Company.
Executive Departure • Aug 28Company Secretary & Compliance Officer Palakben Joshi has left the companyOn the 25th of August, Palakben Joshi's tenure as Company Secretary & Compliance Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Palakben's name. Palakben is the only executive to leave the company over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
